Healthcare

Addiction Biotech Cannabis Genetics Healthcare Medical Devices Pharmaceutical Science Veterinary
News Release Digital Asset Direct

AmeriLife & The American Home Life Insurance Company Team Up to Launch Medicare Supplement & Financial Expense Combo Solution

AmeriLife

AmeriLife Group, LLC (“AmeriLife”), a national leader in developing, marketing, and distributing life and health insurance, annuities, and retirement planning solutions, today announced the launch of a ground-breaking, Medicare Supplement/final expense combination solution developed in partnership with The American Home Life Insurance Company (AHL) and designed to deliver two great products together to better address customers’ holistic needs. “We are extremely excited to partner with AmeriLife to offer highly competitive Medicare Supplement and Final Expense products intentionally designed to facilitate combination sales,” said Tom Lobell, executive vice president and chief marketing officer of AHL. “Between our one-of-a-kind e-app technology, which enables both applications to be completed simultaneously from a single enrollment, and the extensive cost savings clients can access by bundling products, combination sales will never be easier.” For customers, AHL’s Medicare Supplement and Patriot Series final expense products work in tandem to deliver the freedom provided by traditional Medicare along with the peace of mind in knowing their loved ones will not have to bear the burden of their funeral costs. In addition to highly competitive rates, The Patriot Series features a simple, electronic application process, instant underwriting, and seamless premium payments via direct billing through Social Security. For agents, the combination is game-changing. Once clients have qualified for the Medicare Supplement plan, they’re a few questions away – with no phone call required – from being accepted for their discounted, super-preferred Patriot Series final expense policy. And with a discount of up to 20% when combined with the Medicare Supplement plan, agents will help save their clients money year after year and improve client retention. “This new solution is the rewarding combination agents and clients have been waiting for,” said David Paul, national sales director for Simplified Issue Life at AmeriLife. “With a front-loaded commission structure alongside generous bonuses, agents don’t have to let their marketing costs be a roadblock to success – especially while agents learn a new product to better cover their clients’ holistic needs.” “It’s rare that you see a solution with more benefits and less complexity, but this unique combination achieves exactly that,” added Greg Etchison, vice president of Medicare Supplement and Specialty Health for AmeriLife. “It’s a solution made with customers in mind – the way insurance was intended to be – and we’re excited with its potential to help grow our agents’ businesses.” The launch of this combo solution continues AmeriLife’s intense focus on delivering innovative product design, and its partnership with AHL remains a testament to the companies’ shared values and approach to developing modern health and financial planning solutions. “Final expense is continuing to have its moment — and for good reason — as individuals reassess their needs, and those of their loved ones, for their final days,” said Pat Fleming, executive vice president, Product Innovation & Corporate Actuary at AmeriLife. “By combining final expense and Medicare Supplement products under one, simple solution, AmeriLife and AHL are bringing to market a holistic solution that is in line with our unique approach to addressing clients’ total health and financial wellbeing.” To learn more about this new combo solution from AmeriLife and AHL, including details on coverage amounts and other benefits, visit ahlpatriotseries.com. ### About AmeriLife AmeriLife’s strength is its mission: to offer insurance and retirement solutions to help people live longer, healthier lives. In doing so, AmeriLife has become recognized as the leader in developing, marketing, and distributing life and health insurance, annuities and retirement planning solutions to enhance the lives of pre-retirees and retirees across the United States. For more than 50 years, AmeriLife has partnered with top insurance carriers to provide value and quality to customers served through a national distribution network of over 300,000 insurance agents and advisors, more than 50 marketing organizations, and 50 insurance agency locations. For more information, visit AmeriLife.com, and follow AmeriLife on Facebook and LinkedIn. About The American Home Life Insurance Company The American Home Life Insurance Company (AHL) was founded in 1909 in Topeka, Kansas, under the name Kansas Home Mutual Life Insurance Company. In 1912, the Company merged with the American Mutual Life Insurance Company of McPherson, Kansas, and adopted its current name, The American Home Life Insurance Company, which the company has operated under for over 100 years. Throughout the last century, AHL’s mutual corporate structure, conservative investment philosophy, and Midwestern value-oriented culture have enabled it to grow and prosper through multiple world wars, epidemics and recessions while fulfilling its commitments to its policyholders, agents and employees. To learn more, visit amhlifeco.com. Contact Details AmeriLife Jeff Maldonado +1 321-297-1112 jmaldonado@amerilife.com The American Home Life Insurance Company Tom Lobell +1 800-876-0199 tlobell@amhomelife.com Company Website https://amerilife.com/

June 01, 2022 09:00 AM Eastern Daylight Time

The Greeley Company Announces Line-Up of Professional Education In-Person Seminars for Physician and Hospital Leadership

Greeley

The Greeley Company (Greeley), a leader in healthcare education, is pleased to announce that its acclaimed in-person educational seminars for physicians and hospital leaders are slated for the rest of 2022 and into 2023. Participants can register now for all seminars by visiting Physician & Hospital Leadership Seminar | Greeley. The one- to three-day physician-led learning opportunities provide new and emerging leaders with essential training needed to address complex challenges and are all Continuing Medical Education accredited. In addition to core offerings that every individual or team can benefit from including Medical Executive Committee Institute, Peer Review Boot Camp, and The Credentialing Solution, innovative sessions covering today’s top-of-mind issues have been added. One new session debuting in October: Reliability, Resilience, & Risk: Why High Reliability is Critical to Quality and Safety Improvement, addresses the ongoing challenge of delivering on the essential promise of healthcare–helping people at their most vulnerable. “Achieving high reliability will result in clinical outcomes that are safer, more effective, and more equitable, while also improving employee engagement at a critical time for the healthcare workforce,” said Andrew Resnick, Chief Medical and Quality Officer of The Chartis Group. “Our transformational approach will help embed high reliability into your organization, and we look forward to helping you succeed.” Here is the calendar of in-person events: September 23, 2022 in Philadelphia, PA October 27-29, 2022 in Scottsdale, AZ November 4-5, 2022 in Dallas, TX December 8-10, 2022 in Carlsbad, CA January 19-21, 2023 in Orlando, FL To ensure the wellbeing of all attendees, safety protocols will be developed and followed at the events. More information on the programs, including registration and pricing, is available on Greeley's website. About The Greeley Company The Greeley Company (Greeley), a division of The Chartis Group®, is a leader in healthcare consulting, education and interim staffing solutions, with unmatched experience in regulatory compliance, accreditation, bylaws and peer review, as well as credentialing and privileging. Greeley has utilized its proven methodology to help organizations improve efficiency, comply with regulations and standards, achieve practitioner engagement and alignment, and excel in delivering high-quality, cost-effective patient care for more than 30 years. For more information, visit greeley.com. About The Chartis Group® The Chartis Group (Chartis) provides comprehensive advisory services and analytics to the healthcare industry. With an unparalleled depth of expertise in strategic planning, performance excellence, informatics and technology, digital and emerging technologies, and health analytics, Chartis helps leading academic medical centers, integrated delivery networks, children's hospitals and healthcare service organizations achieve transformative results. Chartis has offices in Atlanta, Boston, Chicago, New York, Minneapolis and San Francisco. For more information, visit chartis.com. Contact Details Brooke Ferreri +1 212-931-6182 bferreri@hotpaperlantern.com Company Website https://greeley.com/

May 31, 2022 02:00 PM Eastern Daylight Time

New Cannabis Testing to Help Growers Manage, Prevent Microbial Outbreaks

MCR Labs

Local cannabis testing laboratory MCR Labs has released a new testing suite designed to diagnose microbial issues and determine the best path forward for successful remediative measures. This new service can prevent future outbreaks by allowing cultivators to monitor their grow environment closely for any potential contamination sources, avoiding a full-on outbreak altogether. “It’s really a game changer for growers, as microbial outbreaks are not an ‘if’ but a ‘when’ issue,” said Jonathan Wani, MCR’s director of Business Development. “The biggest value for them is identifying the specific species behind the outbreak. Once you know what species you’re working with, you can develop a targeted remediation plan that’s going to be much more effective than a generic remediative method.” Environmental Monitoring is the latest addition to MCR’s arsenal of plant health services, following the release of Speciation and Plant Nutrition. These tools are meant to provide cultivators with actionable data on their grow to aid in the production of happy, healthy plants. “What we don’t want to do is just fail producers on these mandatory microbiological screens and leave them hanging,” said Michael Kahn, CEO & Founder of MCR Labs. “We’re here to assist cultivating a healthy plant, and therefore a safe product for the consumer.” MCR Labs is licensed as an independent testing laboratory in both the Medical and Adult Use Marijuana programs, which are overseen by the Massachusetts Cannabis Control Commission (CCC). The lab also offers their services to home growers, patients, researchers, or curious consumers. About MCR Labs: MCR Labs is one of the longest operational cannabis testing laboratories on the East coast with facilities operating in several legal cannabis markets. We are ISO/IEC 17025:2017 accredited providers of analytical cannabis product testing and R&D services committed to assisting licensed marijuana establishments, patients, researchers, entrepreneurs, and advocates. Our team of chemists and pharmaceutical scientists are dedicated to advancing public health and safety through leading-edge chemical analysis of cannabis products and offering unparalleled guidance and support for partners, regulators, and the communities we serve. For more information visit http://mcrlabs.com. Contact Details MCR Labs Alexandra Gomes +1 508-782-9772 alexandra@mcrlabs.com Company Website http://mcrlabs.com

May 31, 2022 12:19 PM Eastern Daylight Time

Image

Communication Service for the Deaf Welcomes Shireen Hafeez to its Board of Directors

Communication Service for the Deaf

Communication Service for the Deaf (CSD) is proud to announce the addition of Shireen Hafeez to its Board of Directors. Hafeez joins eight other board members who guide CSD’s overall strategies, promote innovative thinking about the future of CSD, and strategize ways to unleash transformational impact in the Deaf and hard of hearing community. Shireen Hafeez is the founder of Deaf Kids Code, a first-of-its-kind nonprofit that teaches Deaf and hard of hearing children computer and technology skills so they can be economically and socially successful in life. The national outreach organization has worked with more than 9,000 children in over 40 locations around the United States. Hafeez founded Deaf Kids Code to support future generations of Deaf children, including her son, so they can thrive in ways that previous generations couldn’t due to societal and linguistic barriers. “It is the greatest honor to join the board of directors,” said Hafeez. “The most important and exciting part of this role is creating meaningful learning and workforce experiences. It is the greatest privilege to be able to work with like-minded people and create new pathways that didn’t exist before.” Deaf Kids Code is founded on the belief that the digital age is the great equalizer. The organization empowers Deaf and hard of hearing children by equipping them with the technology and design skills they need to succeed in today’s competitive workforce. By teaching them the universal language of computing, students have more substantial opportunities to enter top-tier colleges and pursue fulfilling careers in technology. “Deaf Kids Code is a tremendous success and an important resource for our community to promote and advance STEM education and career pathways,” said CSD CEO Chris Soukup. “Shireen’s experience and expertise aligns beautifully with the outcomes CSD aspires to achieve.” Together, Hafeez and CSD will continue developing strategies to further their shared missions of expanding access to technology and economic opportunities for children and adults who are Deaf or hard of hearing. “Shireen is a longtime ally of the Deaf community, and we are excited to have her join us,” said Board Chair Rogelio Fernandez. “Her unique and valuable perspective will help us shape the future of our organization and community for generations to come.” About Communication Service for the Deaf Communication Service for the Deaf (CSD) is the largest Deaf-led social impact organization in the world. For more than four decades, CSD has been a leader in creating and providing accessible and innovative solutions for the Deaf community. Today, CSD continues its work to create opportunities for personal and economic growth within the Deaf community, specifically addressing leadership and employment. For more information, please visit CSD and follow us on Facebook, Twitter, Instagram, and LinkedIn. Contact Details Leila Eltouny leltouny@csd.org Company Website https://www.csd.org/

May 31, 2022 11:42 AM Eastern Daylight Time

Image

North Texas Municipal Water District Completes One of Nation’s Largest Environmental Restoration Projects

North Texas Municipal Water District

North Texas Municipal Water District (NTMWD), in collaboration with Resource Environmental Solutions (RES), is celebrating the completion of one of the largest environmental restoration projects of its kind in the U.S. After four years of dedicated efforts, North Texas is now home to a new and growing forest of 6.3 million trees, thousands of acres of enhanced wetlands and grasslands and 70 miles of improved streams. This thriving, renewed ecosystem was completed as part of the Bois d’Arc Lake project, the first major reservoir built in Texas in 30 years. NTMWD provides drinking water to more than 2 million people, and the new lake is necessary to meet needs for one of the fastest growing regions in the country. The lake is currently filling with water delivery scheduled for Spring 2023. In addition to providing this critical water supply, the lake will offer recreation and economic benefits. The environmental improvements help offset, or mitigate, the loss of local natural habitat associated with construction of Bois d’Arc Lake. They cover approximately 17,000 acres and will have a legacy that extends for generations to come. NTMWD purchased the Upper Bois d’Arc Creek Mitigation Site and approximately 15,000 acres located along the Red River north of Monkstown, Texas, formerly known as Riverby Ranch. The U.S. Army Corps of Engineers Permit requires the size of mitigated areas to be similar to those inundated by a reservoir. Bois d’Arc Lake has a surface area of 16,641 acres. NTMWD’s goal was to go beyond meeting the regulatory permit requirements: The District chose to restore the land to its pre-agricultural condition. The Riverby area was entirely forested before it was converted to a working cattle ranch. The four-year mitigation efforts included planting 6.3 million trees, restoring and enhancing over 8,500 acres of wetlands, restoring 70 miles of existing streams, including sections of Willow Branch Creek, and planting approximately 3,200 acres of native grassland. This is the final year of active planting and restoration activities. Trees function as the pillar of thriving North Texas ecosystems. Earlier this year, the last several million native saplings were planted at the ranch and neighboring Upper Bois d’Arc Lake Mitigation Area. The trees were added in one to two million increments over the previous four years, with crews filling in areas as needed to establish resilient, mature forests. To better support streambanks, crews also planted live stakes, which are branches cut from black willows, cottonwoods and sycamores that grow into new trees. “Trees support complex ecosystems for wildlife, help control erosion and flooding and improve air quality,” explained RES Project Manager Matt Stahman. “All the work—stream restoration, tree planting and grass establishment—was done concurrently to create thriving ecosystems. The trees help keep sediment out of the streams, and in turn they benefit from water provided by the restored streams.” Less erosion in the lake’s watershed and waterways will decrease sedimentation and nutrient loads into Bois d’Arc Creek, the Red River and surrounding topography and improve the lake’s overall water quality. More than a million more trees were planted than originally planned, due to the need for categorizing and replanting some habitat areas. “It takes time to learn which habitats work best in each area,” said RES Project Ecologist Brandon Hall. “We came up with a plan, but our job is to work with what nature wants to do. There were some areas that we labeled in the plan as grasslands, but they ended up being better restored as forest, and vice versa. So we replanted more trees accordingly.” “The main lesson we learned was to work with and not against nature,” agreed Daniel Kampfer, RES Project Superintendent for the mitigation process. “Now we will take everything we’ve learned here—the successes as well as the setbacks—and work even more effectively and efficiently on the next large-scale restoration project.” The restoration team initially sectioned the restoration areas into 300 larger habitat sections, with trees selected for planting in some of these areas. Ultimately, over 670 habitat areas were identified and individually restored. The result of these careful designations and restoration of trees, rivers and other habitats is a highly resilient landscape that supports a diverse set of inhabitants, including pollinators, predators and birds of prey. According to Jim Bednarz, Senior Lecturer at the University of North Texas, the first signs of successful restoration is a diverse community of birds and animals, especially those at the top of the food chain—the predators. “Our preliminary data has already shown a huge number of birds of prey,” Bednarz said. Master’s degree students from the university have been onsite analyzing avian life and identified over a hundred bird species, including many that are threatened or protected in the state of Texas. RES highlighted this important research project which is available to watch online. Now that active restoration efforts are concluding, NTMWD and RES will transition to monitoring and maintenance for decades to ensure that the entire site continues to thrive. While all the new habitats must be monitored, “a lot of our ongoing efforts will be forestry, to develop those saplings and live stakes into the tree stands,” Stahman said. Teams will track the number of stands and types of trees per acre, including those that didn’t make it. Watch this video produced by RES for a stunning overview of the project and its transition to maintenance. “Think of it like a garden,” Hall explained. “The construction phase of a garden includes planting and tilling, but then it requires weeding and possibly planting a trellis and so forth to maintain. Our work is similar, just on a much larger, 17,000-acre scale.” For more information on Bois d’Arc Lake and its extensive environmental improvements, visit BoisdArcLake.org. About Bois d’Arc Lake Bois d’Arc Lake is the first major reservoir to be built in Texas in over 30 years. Located in Fannin County, the lake is owned and operated by the North Texas Municipal Water District. While the lake’s primary purpose is to provide drinking water to one of the fastest growing regions in the country, it will also offer future water recreation and outdoor activities. About NTMWD The North Texas Municipal Water District (NTMWD) was created in 1951 as a special district of the state. Today, NTMWD is a regional wholesale provider of water, wastewater, and solid waste disposal services for approximately two million residents across 10 counties – a service territory covering 2,200 square miles. With an annual operations budget of $570 million and 900 employees, NTMWD serves up to 80 communities with drinking water, more than 1.4 million people with wastewater collection and treatment, about 930,000 people with waste management services, and operates one of the largest advanced water treatment plants with a capacity of 876 million gallons per day. About RES Resource Environmental Solutions serves as the nation’s only fully scaled operating company, providing comprehensive ecological restoration and water resource solutions that build and sustain natural resiliency in local ecosystems. Contact Details North Texas Municipal Water District Wayne Larson, Director of Communications +1 214-449-8092 wlarson@ntmwd.com Company Website https://www.ntmwd.com/

May 31, 2022 09:10 AM Central Daylight Time

Image

SleepX approved by the Helsinki Committee to conduct clinical trial with the SleepX PRO smartphone application

Appyea

SleepX, a subsidiary of AppYea (OTC: APYP) focusing on the development of accurate wearable monitoring solutions to treat sleep apnea and snoring, announces it received approval from the Helsinki Committee to begin its planned clinical trial on the SleepX PRO application. This follows the company’s recent update that it intends to test the SleepX Pro application at a hospital sleep lab. The trial is the first step towards applying for an FDA approval under the first-of-its-kind medical device category for contactless detection of sleep apnea to be performed through the Artificial Intelligence (AI) analysis of breathing during sleep. SleepX Pro, which is designed to diagnose sleep apnea using only a smartphone, requires no physical contact with the subject. Global Smart Sleep Tracking Products Market to Garner a Revenue of USD 11,234.55 Million by 2028 and Grow with a CAGR of 17.50% during 2020-2028; Surge in Concern for Sleep-Related Disorders to Drive the Market Growth, according to Kenneth Research (May 16, 2022). “Poor sleep is associated with the compromised immune system, heart problems, reduce physical and mental performance, mood problems, obesity and many other health problems”, said Neil Kline, Founder & former CEO of the American Sleep Association, and a AppYea Board Member. “Unfortunately, most people with sleep disorder breathing problems, like sleep apnea, are undiagnosed and untreated. Our goal in this unique technology is to raise the awareness to the problem and to improve people’s they can live healthier and more fulfilling lives.” “SleepX PRO makes for a unique, quick and friendly diagnosis tool that will prevent subjects from having to spend nights at sleep labs while saving the healthcare system and insurance companies hundreds of millions of dollars”, said Boris (Bary) Molchadsky, President and CEO of SleepX, and Chair at AppYea. “We plan to make our diagnosis solution highly accessible so people get tested easily. SleepX is an Israeli research and development company recently acquired by AppYea. The company had developed a unique product for monitoring and treating sleep apnea and snoring. The technology is protected by several international patents and the company plans to start serial production in 2022. The company currently focuses its activities on the development and commercialization of its flagship product DreamIT. Legal Notice Regarding Forward-Looking Statements This release includes forward-looking statements. Such statements involve risks and uncertainties which could cause actual results to differ materially from those set forth herein. No statement herein should be considered an offer or a solicitation of an offer for the purchase or sale of any securities. Although APYP believes that the expectations reflected in the forward-looking statements and the assumptions upon which they are based are reasonable, it can give no assurance that such expectations and assumptions will prove to have been correct. Forward-looking statements, which involve assumptions and describe our future plans, strategies, and expectations, are generally identifiable by use of the words "may," "will," "should," "could," "expect," "anticipate," "estimate," "believe," "intend," or "project" or the negative of these words or other variations on these words or comparable terminology. The reader is cautioned not to put undue reliance on these forward-looking statements, as these statements are subject to numerous factors and uncertainties, including but not limited to adverse economic conditions, intense competition, entry of new competitors and products, adverse federal, state and local government regulation, inadequate capital, unexpected costs and operating deficits, increases in general and administrative costs, unanticipated losses, financial condition and stock price, inability to carry out research, development and commercialization plans and other specific risks. APYP does not undertake any obligation to publicly update any forward-looking statement. Neither APYP nor SLEEPX are subject to the reporting requirements of the Securities and Exchange Commission under the Securities and Exchange Act of 1934 as amended. Contact Details Asaf Porat +1 800-674-3561 info@appyea.com Company Website http://www.appyea.com

May 31, 2022 08:30 AM Eastern Daylight Time

Kadimastem Awarded Patent in Japan for AstroRx® For ALS and Drug Screening

Kadimastem

Kadimastem Ltd. (TASE: KDST), a clinical stage cell therapy company developing a treatment for ALS, exploring one for multiple sclerosis and developing a potential cure for diabetes, has received a patent from the Japan Patent Office for AstroRx ® for the treatment of ALS and drug screening. The patent also protects AstroRx® for the treatment of multiple sclerosis. AstroRx® is comprised of a differentiated cell population of human astrocytes derived from human pluripotent stem cells. The cells are intended to support the central nervous system (brain and spinal cord), impaired by neurological diseases such as ALS and multiple sclerosis, which disrupt voluntary muscle movement. In a first of its kind Phase I/IIa clinical trial, healthy and functioning astrocyte cells (AstroRx®) were injected into the spinal cord fluid of 10 ALS patients in a standard lumbar puncture. Data showed that AstroRx® delayed the progression of ALS by three months in ALSFRS-R measurement in both tested AstroRx doses. In the next clinical trial of AstroRx®, the plan is to test if this three-month effect can be prolonged with repeated doses every three months of the off-shelf product of AstroRx®. Kadimastem remains on track to submit an IND to the FDA before the end of 2022 to begin a multicenter clinical trial of AstroRx® for ALS in 2023 in the U.S. Kadimastem CEO Asaf Shiloni said, “The Japanese patent strengthens our intellectual property and gives our cell therapy products top priority in the very important and large Southeast Asian region of the world. In addition, we are exploring the possibilities of business partnerships with the pharmaceutical industry in Japan, both for AstroRx® for ALS and IsletRx for diabetes.” Kadimastem Chief Scientist Professor Michel Revel said, "Japan is a prominent territory. This patent protects a significant and highly unique technology and provides a solid IP advantage for Kadimastem." The Japanese market is one of the most significant for stem cell-derived cell therapies. Japan has strategic importance in this field, as it is at the forefront of the international community supporting innovation and the development of products in the field of cell therapy. In November 2014, the Japanese Parliament approved a special law 1 to facilitate clinical trials in the field of cellular medicine, with the aim of expediting approvals of intracellular therapies and quickly bringing them to market. Japan has more than 12,000 ALS patients and this number continues to increase as the population ages. The treatment of these patients is currently estimated at an annual $ 1 billion 2. [1] Azuma K. Regulatory Landscape of Regenerative Medicine in Japan. Curr Stem Cell Reports. 2015; 1: 118–128. doi:10.1007/s40778-015-0012-6 [2] Doi et al., J Epidemiol. 2014; 24(6): 494–499. doi: 10.2188/jea.JE20140059. Prevalence of ~0.01 of Japanese population of 125 M (https://worldpopulationreview.com/countries/japan-population) =12,500 About Kadimastem: Kadimastem is a clinical stage cell therapy company, developing and manufacturing "off-the-shelf", allogeneic, proprietary cell products based on its technology platform for the expansion and differentiation of Human Embryonic Stem Cells (hESCs) into functional cells. AstroRx®, the Company's lead product, is an astrocyte cell therapy in clinical development as a treatment for ALS. IsletRx is the Company's second product in development. IsletRx is comprised of functional pancreatic islet cells intended to treat patients with insulin dependent diabetes. IsletRx demonstrated safety and efficacy in a proof-of-concept preclinical study. Kadimastem was founded by Professor Michel Revel, CSO of the Company and Professor Emeritus of Molecular Genetics at the Weizmann Institute of Science. Professor Revel received the Israel Prize for the invention and development of Rebif®, a multiple sclerosis blockbuster drug sold worldwide. Kadimastem is traded on the Tel Aviv Stock Exchange (TASE: KDST). Forward Looking Statement: This document may include forward-looking information as defined in the Securities Law, 5728 – 1968. Forward-looking information is uncertain and mostly is not under the Company's control and the realization or non-realization of forward-looking information will be affected, among other things, by the risk factors characterizing the Company's activity, as well as developments in the general environment and external factors affecting the Company's activity. The Company's results and achievements in the future may differ materially from any presented herein and the Company makes no undertaking to update or revise such projection or estimate and does not undertake to update this document. This document does not constitute a proposal to purchase the Company's securities or an invitation to receive such offers. Investment in securities in general and in the Company in particular bears risks. One should consider that past performance does not necessarily indicate performance in the future. Contact Details Kadimastem Asaf Shiloni +972 73-797-1613 s.bazak@kadimastem.com Must Have Communications Marjie Hadad +1 917-790-1178 marjie@mhc-pr.com Company Website https://www.kadimastem.com/

May 30, 2022 09:10 AM Eastern Daylight Time

Image

Hong Kong Baptist University-led research identifies new regulatory mechanism of satiety and therapeutic target for obesity

Hong Kong Baptist University

HONG KONG SAR - Media OutReach - 30 May 2022 - A research team led by Hong Kong Baptist University (HKBU) has found that a proteolytic enzyme called membrane-type 1 matrix metalloproteinase ( MT1-MMP) plays an important role in the regulatory mechanism of fullness, or satiety, and it could serve as a promising potential drug target for the management of obesity. Dr Xavier Wong Hoi-leong, Assistant Professor of the Teaching and Research Division of the School of Chinese Medicine (left), and Professor Bian Zhaoxiang, Director of the Clinical Division of the School of Chinese Medicine and Tsang Shiu Tim Endowed Chair of Chinese Medicine Clinical Studies at HKBU (right), identified a proteolytic enzyme called MT1-MMP which could serve as a promising potential drug target for the management of obesity. The research findings were published in the internationally-renowned scientific journal Nature Metabolism. The study has also been featured as a research highlight in multiple high-impact journals, including Nature Reviews Endocrinology, Nature Metabolism and Science Signaling. Half of Hong Kong’s population obese or overweight Being overweight, especially to the extent of obesity, exposes people to a higher risk of life-threatening diseases such as cardiovascular diseases, diabetes, and cancer. According to the Population Health Survey conducted in 2014/15 by the Department of Health, about 30% of people in Hong Kong aged 15 to 84 were obese, and another 20% were overweight. The most effective way to tackle obesity is to reduce food consumption, but obese people often encounter difficulties in regulating their dietary habits as they lose their sense of satiety. Identifying a factor that specifically controls body weight, and investigating how it regulates our sense of satiety, is crucial for the development of therapeutic approaches for obesity. Identification of new regulator of satiety signals A research team led by Dr Xavier Wong Hoi-leong, Assistant Professor of the Teaching and Research Division of the School of Chinese Medicine (SCM), and Professor Bian Zhaoxiang, Director of the Clinical Division of SCM and Tsang Shiu Tim Endowed Chair of Chinese Medicine Clinical Studies at HKBU, identified a proteolytic enzyme called MT1-MMP which regulates the mechanism of issuing satiety signals in the human brain. Growth and differentiation factor 15 (GDF15) is a hormone that sends out satiety signals by binding with the neuron receptor in the hindbrain called GDNF-family receptor α-like (GFRAL). Mediation of GFRAL can therefore affect the ability of GDF15 to send satiety signals, and thus help regulate food intake. From this starting point, the research team conducted a series of experiments to investigate the mediation effects of MT1-MMP on GFRAL. Depletion of MT1-MMP reduces obesity The research team generated an obesity mouse model by feeding a fat-rich diet to a group of transgenic mice with a depletion of MT1-MMP in their satiety neurons, as well as a control group of ordinary mice. After 16 weeks, the mice with depleted MT1-MMP ate 10% less food, gained 50% less weight, and exhibited reduced glucose and plasma insulin levels compared to the control group. The results show that depletion of MT1-MMP protects mice from obesity induced by a high-fat diet. Following analysis with western blots, a widely used analytical technique that can detect specific proteins, the research team also found that the obese mice displayed an increased activity of MT1-MMP in the Area Postrema and Nucleus of the Solitary Tract, the brain regions involved in appetite and weight regulation. The finding suggests that increased MT1-MMP activity in the brain of obese mice could be a risk factor causing sustained weight gain. To understand the mechanism by which MT1-MMP suppresses GDF15 satiety signalling, the research team conducted a series of molecular biology experiments involving animal models and cell culture. The results show that in cells with active MT1-MMP, a significant reduction of GFRAL and thus GDF15 signalling were observed. It could be explained by MT1-MMP clipping GFRAL from the surface of the brain neurons, which blocks GDF15 from binding to GFRAL and thus reduces the number of satiety signals. This in turn keeps the neurons from transmitting the satiety signals sent by GDF15. MT1-MMP as a therapeutic target for obesity The researchers also explored the therapeutic potential of targeting MT1-MMP for obesity management, in particular through pharmacological inhibition of its activity in vivo. With the application of a specific neutralising antibody that inhibits MT1-MMP, significant improvements in metabolic parameters including food intake, glucose tolerance and body weight in obese mice were observed. The results suggest that MT1-MMP is a potential therapeutic target that could be used in the development of innovative drug treatments for obesity. Dr Wong said: “The research findings have established the role played by MT1-MMP in regulating satiety, and they have provided preliminary indications that the proteolytic enzyme is a promising target for the treatment of obesity. Pharmacological inhibition of MT1-MMP could be a viable strategy for the development of effective pharmacotherapy for the treatment of obesity.” Apart from researchers from HKBU, the research team included scientists from The University of Hong Kong, The Chinese University of Hong Kong, the University of Texas Health Science Center at Houston, and the University of Helsinki. #HongKongBaptistUniversity #HKBU Contact Details Christina Wu from the Communication and Public Relations Office +852 3411 7828 christinawu@hkbu.edu.hk Company Website https://www.hkbu.edu.hk/

May 30, 2022 04:26 AM Eastern Daylight Time

Image

Nutritional Supplement Manufacturer Nutramax Laboratories Exceeds Industry Standards for Quality

Nutramax Laboratories

For 30 years, Nutramax Laboratories has diligently adhered to industry-leading quality controls and manufacturing standards. This commitment to quality has been affirmed by Nutramax’s utilization of third-party, independent auditing and certification programs. Nutramax Laboratories recently completed a rigorous conformance assessment for the GMP certification program administered by Underwriters' Laboratories (UL), the global safety science leader in auditing and certification. The annual certification covers a full GMP audit criterion based on 21 CFR Part 111, Good Manufacturing Practices for dietary supplements. This marks the third year of the UL Certificate of Conformance program; the successful audits featuring three different auditors are a testament to the quality systems, facilities, equipment, processes, and the superb employees of Nutramax. Nutramax’s quality procedures include rigorous testing and inspection at every stage of the manufacturing process and go above and beyond the standards governing the industry. “ We choose to go above and beyond what is required because it is the only way to be certain that the products released for sale meet a defined set of the quality standards that our customers deserve,” says Godwin Omorogieva, Vice President of Quality at Nutramax. As the #1 veterinarian recommended supplement company, Nutramax Laboratories Veterinary Sciences has earned the trust of its valued customers by providing them with innovative products that are backed by science and held to the highest standard. “Supporting the health of pets is our priority,” says President and CEO, Todd Henderson, DVM. “In our ongoing pursuit of excellence for the next 30 years, and beyond, we pledge our loyalty to customers with a continued commitment to uphold the highest standards in quality control, manufacturing, and research.” Nutramax Laboratories Veterinary Sciences’ products are manufactured in state-of-the-art facilities in accordance with Good Manufacturing Practices (GMPs) and a strict set of Standard Operating Procedures (SOPs). It has long been their tradition to back each supplement with scientific studies that support their safety and efficacy, ensuring that customers can be confident that what the packaging states, can be trusted. For more information on the Nutramax Laboratories quality standard, visit nutramaxlabs.com/our-quality or speak to a dedicated Customer Service team member at (888) 886-6442. Nutramax Laboratories Veterinary Sciences, Inc. develops, and markets supplements backed by research for companion animals to help support their quality of life. Small animal products include Cosequin®, the #1 Veterinarian Recommended Retail Joint Health Supplement Brand*,**; Dasuquin®, the #1 veterinarian-recommended joint health supplement brand*; the #1 veterinarian-recommended liver support brand Denamarin®***; and products supporting urinary tract health, digestive health, and skin/coat health plus overall wellness. To learn more, call (888) 886-6442 or visit nutramaxlabs.com. *Source: Among retail brands. Survey conducted among small animal veterinarians who recommend oral joint health supplements. **Source: Among veterinary brands. Survey conducted among small animal veterinarians who recommended oral joint health supplements. ***Source: Survey conducted among small animal veterinarians who recommended liver support brands. Contact Details Erika Dyer +1 703-906-6368 erika@curleycompany.com Company Website https://www.nutramaxlabs.com/

May 26, 2022 09:48 AM Eastern Daylight Time

1 ... 222 223 224 225 226 ... 306